Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: Clinical activity and molecular markers

Abstract

Histone deacetylase inhibitors induce changes in gene expression that lead to cellular differentiation and reversal of the transformed phenotype. In addition, acetylation of centromeric chromatin and non-histone proteins also likely plays a role in cytotoxicity due to romi depsin. Interest in clinical development of these agents has been spurred by the responses observed in patients with peripheral or cutaneous T-cell lymphoma to romidepsin, previously FK228 or depsipeptide.